Journal of Advanced Biotechnology and Experimental Therapeutics (Apr 2022)

Mucormycosis (black fungus) and its impact on the COVID-19 patients: An updated review

  • AKM Moyeenul Huq,
  • Md. Golzar Hossain,
  • Md. Saiful Islam,
  • Md. Abdus Sobur,
  • AMM Taufiquer Rahman,
  • Md.Tanvir Rahman

DOI
https://doi.org/10.5455/jabet.2022.d108
Journal volume & issue
Vol. 5, no. 1
pp. 198 – 217

Abstract

Read online

Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a global pandemic of the century. The disease is wreaking havoc on human health, the world economy, society, and the environment. It has already caused the loss of millions of lives. Because of the mutation, the virus is constantly evolving itself, changing its nature including the disease transmission rate, virulence, pathogenesis, and clinical manifestations. It was recently reported that certain COVID-19 patients are also suffering from a fungal infection as co-infection commonly known as mucormycosis (black fungus). In India, the outbreak of black fungus in COVID-19 patients has already been declared an epidemic. Only a few reports are noticed in other countries. The focus must now be put toward better management and control of the COVID-19-associated fungal infection. In this review, we have discussed various aspects of black fungus particularly the etiology, taxonomy, risk factors, transmission, pathogenesis, clinical manifestations, diagnosis, and line of treatment to keep up to date on how to manage this fungal infection better. [ J Adv Biotechnol Exp Ther 2022; 5(1.000): 198-217]

Keywords